Chemoimmunomodulation: Immune regulation by the antineoplastic chemotherapeutic agents

Current Medicinal Chemistry

Volumn 19, Issue 12, 2012, Pages 1792-1803

  Shurin, M R ^a,b   Naiditch, H ^a   Gutkin, D W ^a,c   Umansky, V ^d   Shurin, G V ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemoimmunomodulation; Chemomodulation; Chemotherapy; Immunostimulation; Immunosuppression; Paclitaxel

Indexed keywords

ACEDAPSONE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CLADRIBINE; COLCHICINE; CYCLOPHOSPHAMIDE; CYTARABINE; DIMETHYLBUSULFAN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; METHOTREXATE; MITOMYCIN C; PACLITAXEL; VALRUBICIN; VINBLASTINE; VINCRISTINE;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CYTOTOXICITY; DENDRITIC CELL; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; LEUKOPENIA; NEUTROPENIA; NONHUMAN; SIDE EFFECT; SINGLE DRUG DOSE; T CELL DEPLETION; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; NEOPLASMS; T-LYMPHOCYTES;

EID: 84860501672     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800099785     Document Type: Article

References (134)

1. Hirsch, J. An anniversary for cancer chemotherapy. Jama, 2006, 296, 1518-1520. (Pubitemid 44465516)
2. Krumbhaar, E. B. Role of the blood and the bone marrow in certain forms of gas poisoning. JAMA, 1919, 72, 39-41.
3. Adair, F. E.; Bagg, H. J. Experimental and clinical studies on the treatment of cancer by dichlororethylsulphide (mustard gas). Ann Surg, 1931, 93, 190-199.
4. Joensuu, H. Systemic chemotherapy for cancer: from weapon to treatment. Lancet Oncol, 2008, 9, 304. (Pubitemid 351722950)
5. Goodman, L.; Wintrobe, M.; Dameshek, W.; Goodman, M.; Gilman, A.; McLennan, M. Nitrogen mustard therapy: use of methyl-bis (betachloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders. JAMA, 1946, 132, 126-132.
6. Rhoads, C. P. The Edward Gamaliel Janeway Lecture: the sword and the ploughshare. J Mt Sinai Hosp., 1946, 13, 299-309.
7. Goodman, L. S.; Wintrobe, M. M.; Dameshek, W.; Goodman, M. J.; Gilman, A.; McLennan, M. T. Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan. JAMA, 1984, 251, 2255-2261. (Pubitemid 14135443)
8. Farber, S.; Diamond, L. K.; Mercer, R. D.; Sylvester, R. F.; Wolff, J. A. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-Aminopteroyl-glutamic acid (Aminopterin). N Engl J Med, 1948, 238, 787-793.
9. Steele, T. A. Chemotherapy-induced immunosuppression and reconstitution of immune function. Leuk Res, 2002, 26, 411-414. (Pubitemid 34143059)
10. Rasmussen, L.; Arvin, A. Chemotherapy-induced immunosuppression. Environ Health Perspect, 1982, 43, 21-25. (Pubitemid 12108540)
11. Di Lorenzo, G.; Porta, C.; Bellmunt, J.; Sternberg, C.; Kirkali, Z.; Staehler, M.; Joniau, S.; Montorsi, F.; Buonerba, C. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol, 2011, 59, 526-540.
12. Yaal-Hahoshen, N.; Maimon, Y.; Siegelmann-Danieli, N.; Lev-Ari, S.; Ron, I. G.; Sperber, F.; Samuels, N.; Shoham, J.; Merimsky, O. A Prospective, Controlled Study of the Botanical Compound Mixture LCS101 for Chemotherapy-Induced Hematological Complications in Breast Cancer. Oncologist, 2011, 16, 1197-1202.
13. Wijayahadi, N.; Haron, M. R.; Stanslas, J.; Yusuf, Z. Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens. J Chemother, 2007, 19, 716-723. (Pubitemid 351212023)
14. Mita, K.; Ito, H.; Fukumoto, M.; Murabayashi, R.; Nabetani, M.; Koizumi, K.; Hayashi, T. Gemcitabine and s-1 combination chemotherapy in patients with advanced biliary tract cancer: a retrospective study. Case Rep Oncol, 2010, 3, 498-504.
15. Naiditch, H.; Shurin, M. R.; Shurin, G. V. Targeting myeloid regulatory cells in cancer by chemotherapeutic agents. Immunol Res, 2011, 50, 276-285.
16. Bonavida, B. Antigen-induced cyclophosphamide-resistant suppressor T cells inhibit the in vitro generation of cytotoxic cells from one-way mixed leukocyte reactions. J Immunol, 1977, 119, 1530-1533. (Pubitemid 8214780)
17. Goldman, D. Chronic lymphocytic leukemia and its impact on the immune system. Clin J Oncol Nurs, 2000, 4, 233-234, 236.
18. Kim, S. K.; Demetri, G. D. Chemotherapy and neutropenia. Hematol Oncol Clin North Am, 1996, 10, 377-395. (Pubitemid 26097345)
19. Alanko, S.; Salmi, T. T.; Pelliniemi, T. T. Recovery of natural killer cells after chemotherapy for childhood acute lymphoblastic leukemia and solid tumors. Med Pediatr Oncol, 1995, 24, 373-378.
20. Zocchi, M. R.; Poggi, A. Role of gammadelta T lymphocytes in tumor defense. Front Biosci, 2004, 9, 2588-2604.
21. Dmoszynska, A.; Legiec, W.; Wach, M. Attempted reconstruction of the immune system using low doses of interleukin 2 in chronic lymphocytic leukemia patients treated with 2-chlorodeoxyadenosine: results of a pilot study. Leuk Lymphoma, 1999, 34, 335-340. (Pubitemid 29385176)
22. Mackall, C. L.; Fleisher, T. A.; Brown, M. R.; Andrich, M. P.; Chen, C. C.; Feuerstein, I. M.; Magrath, I. T.; Wexler, L. H.; Dimitrov, D. S.; Gress, R. E. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood, 1997, 89, 3700-3707. (Pubitemid 27227093)
23. Azuma, E.; Nagai, M.; Qi, J.; Umemoto, M.; Hirayama, M.; Kumamoto, T.; Hiratake, S.; Komada, Y.; Sakurai, M. CD4+ T-lymphocytopenia in longterm survivors following intensive chemotherapy in childhood cancers. Med Pediatr Oncol, 1998, 30, 40-45. (Pubitemid 128765911)
24. Mackall, C. L. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells, 2000, 18, 10-18. (Pubitemid 30064888)
25. Mustafa, M. M.; Buchanan, G. R.; Winick, N. J.; McCracken, G. H.; Tkaczewski, I.; Lipscomb, M.; Ansari, Q.; Agopian, M. S. Immune recovery in children with malignancy after cessation of chemotherapy. J Pediatr Hematol Oncol, 1998, 20, 451-457. (Pubitemid 29133200)
26. Perrotta, C.; Bizzozero, L.; Falcone, S.; Rovere-Querini, P.; Prinetti, A.; Schuchman, E. H.; Sonnino, S.; Manfredi, A. A.; Clementi, E. Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma. Cancer Res, 2007, 67, 7559-7564. (Pubitemid 47281347)
27. Shin, J. Y.; Lee, S. K.; Kang, C. D.; Chung, J. S.; Lee, E. Y.; Seo, S. Y.; Lee, S. Y.; Baek, S. Y.; Kim, B. S.; Kim, J. B.; Yoon, S. Antitumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model. Histol Histopathol, 2003, 18, 435-447. (Pubitemid 36362061)
28. Nakashima, H.; Tasaki, A.; Kubo, M.; Kuroki, H.; Matsumoto, K.; Tanaka, M.; Nakamura, M.; Morisaki, T.; Katano, M. Effects of docetaxel on antigen presentation-related functions of human monocyte-derived dendritic cells. Cancer Chemother Pharmacol, 2005, 55, 479-487. (Pubitemid 40568979)
29. Jiga, L. P.; Bauer, T. M.; Chuang, J. J.; Opelz, G.; Terness, P. Generation of tolerogenic dendritic cells by treatment with mitomycin C: inhibition of allogeneic T-cell response is mediated by downregulation of ICAM-1, CD80, and CD86. Transplantation, 2004, 77, 1761-1764. (Pubitemid 38780546)
30. Laane, E.; Bjorklund, E.; Mazur, J.; Lonnerholm, G.; Soderhall, S.; Porwit, A. Dendritic cell regeneration in the bone marrow of children treated for acute lymphoblastic leukaemia. Scand J Immunol, 2007, 66, 572-583. (Pubitemid 47609698)
31. Wertel, I.; Polak, G.; Barczynski, B.; Kotarski, J. [Subpopulations of peripheral blood dendritic cells during chemotherapy of ovarian cancer]. Ginekol Pol, 2007, 78, 768-771.
32. Bellik, L.; Gerlini, G.; Parenti, A.; Ledda, F.; Pimpinelli, N.; Neri, B.; Pantalone, D. Role of conventional treatments on circulating and monocytederived dendritic cells in colorectal cancer. Clin Immunol, 2006, 121, 74-80. (Pubitemid 44380419)
33. Ferrari, S.; Rovati, B.; Porta, C.; Alessandrino, P. E.; Bertolini, A.; Collova, E.; Riccardi, A.; Danova, M. Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard-or high-dose chemotherapy plus granulocyte-colony stimulating factor. Cancer Immunol Immunother, 2003, 52, 359-366. (Pubitemid 36693756)
34. Ferraro, C.; Quemeneur, L.; Prigent, A. F.; Taverne, C.; Revillard, J. P.; Bonnefoy-Berard, N. Anthracyclines trigger apoptosis of both G0-G1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T and B cells. Cancer Res, 2000, 60, 1901-1907. (Pubitemid 30207650)
35. Diaz-Montero, C. M.; Salem, M. L.; Nishimura, M. I.; Garrett-Mayer, E.; Cole, D. J.; Montero, A. J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother, 2009, 58, 49-59.
36. Xiao, H.; Verdier-Pinard, P.; Fernandez-Fuentes, N.; Burd, B.; Angeletti, R.; Fiser, A.; Horwitz, S. B.; Orr, G. A. Insights into the mechanism of microtubule stabilization by Taxol. Proc Natl Acad Sci U S A, 2006, 103, 10166-10173. (Pubitemid 44051138)
37. Chuang, L. T.; Lotzova, E.; Cook, K. R.; Cristoforoni, P.; Morris, M.; Wharton, J. T. Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes. Gynecol Oncol, 1993, 49, 291-298. (Pubitemid 23191200)
38. Gangemi, R. M.; Tiso, M.; Marchetti, C.; Severi, A. B.; Fabbi, M. Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother Pharmacol, 1995, 36, 385-392.
39. Marupudi, N. I.; Han, J. E.; Li, K. W.; Renard, V. M.; Tyler, B. M.; Brem, H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf, 2007, 6, 609-621. (Pubitemid 351308218)
40. John, J.; Ismail, M.; Riley, C.; Askham, J.; Morgan, R.; Melcher, A.; Pandha, H. Differential effects of Paclitaxel on dendritic cell function. BMC Immunol, 2010, 11, 14.
41. Robinson, M. J.; Ronchese, F.; Miller, J. H.; La Flamme, A. C. Paclitaxel inhibits killing by murine cytotoxic T lymphocytes in vivo but not in vitro. Immunol Cell Biol, 2010, 88, 291-296.
42. Chuang, L. T.; Lotzova, E.; Heath, J.; Cook, K. R.; Munkarah, A.; Morris, M.; Wharton, J. T. Alteration of lymphocyte microtubule assembly, cytotoxicity, and activation by the anticancer drug taxol. Cancer Res, 1994, 54, 1286-1291. (Pubitemid 24108070)
43. Markasz, L.; Skribek, H.; Uhlin, M.; Otvos, R.; Flaberg, E.; Eksborg, S.; Olah, E.; Stuber, G.; Szekely, L. Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. J Immunother, 2008, 31, 283-293. (Pubitemid 351441005)
44. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat Rev Cancer, 2004, 4, 253-265. (Pubitemid 38525281)
45. Kupfer, A.; Dennert, G. Reorientation of the microtubule-organizing center and the Golgi apparatus in cloned cytotoxic lymphocytes triggered by binding to lysable target cells. J Immunol, 1984, 133, 2762-2766. (Pubitemid 15206939)
46. Wolberg, G.; Stopford, C. R.; Zimmerman, T. P. Antagonism by taxol of effects of microtubule-disrupting agents on lymphocyte cAMP metabolism and cell function. Proc Natl Acad Sci U S A, 1984, 81, 3496-3500. (Pubitemid 14122701)
47. Bunnell, S. C.; Kapoor, V.; Trible, R. P.; Zhang, W.; Samelson, L. E. Dynamic actin polymerization drives T cell receptor-induced spreading: a role for the signal transduction adaptor LAT. Immunity, 2001, 14, 315-329. (Pubitemid 32289295)
48. Das, V.; Nal, B.; Dujeancourt, A.; Thoulouze, M. I.; Galli, T.; Roux, P.; Dautry-Varsat, A.; Alcover, A. Activation-induced polarized recycling targets T cell antigen receptors to the immunological synapse; involvement of SNARE complexes. Immunity, 2004, 20, 577-588. (Pubitemid 38638127)
49. Cersosimo, R. J.; Hong, W. K. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol, 1986, 4, 425-439. (Pubitemid 16133097)
50. Plosker, G. L.; Faulds, D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs, 1993, 45, 788-856. (Pubitemid 23177452)
51. Robert, J.; Gianni, L. Pharmacokinetics and metabolism of anthracyclines. Cancer Surv, 1993, 17, 219-252.
52. Case, D. C., Jr.; Ervin, T. J.; Gams, R.; Sonneborn, H. L.; Paul, S. D.; Oldham, F. B. Phase I-II study of epirubicin in multiple myeloma. Cancer Res, 1988, 48, 6246-6248. (Pubitemid 18266830)
53. Carmichael, J.; Walling, J. Advanced breast cancer: investigational role of gemcitabine. Eur J Cancer, 1997, 33 Suppl 1, S27-30.
54. Facchinetti, T.; Raz, A.; Goldman, R. A differential interaction of daunomycin, adriamycin, and N-trifluoroacetyladriamycin 14-valerate with mouse peritoneal macrophages. Cancer Res, 1978, 38, 3944-3949. (Pubitemid 9046353)
55. Mantovani, A. In vitro and in vivo cytotoxicity of adriamycin and daunomycin for murine macrophages. Cancer Res, 1977, 37, 815-820. (Pubitemid 8051650)
56. Vecchi, A.; Mantovani, A.; Tagliabue, A.; Spreafico, F. A characterization of the immunosuppressive activity of adriamycin and daunomycin on humoral antibody production and tumor allograft rejection. Cancer Res, 1976, 36, 1222-1227.
57. Kushner, B. H.; Cheung, I. Y.; Kramer, K.; Modak, S.; Cheung, N. K. Highdose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. Pediatr Blood Cancer, 2007, 48, 430-434. (Pubitemid 46340109)
58. Steinberg, A. D.; Kaltreider, H. B.; Staples, P. J.; Goetzl, E. J.; Talal, N.; Decker, J. L. Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med, 1971, 75, 165-171.
59. Townes, A. S.; Sowa, J. M.; Shulman, L. E. Controlled trial of cyclophosphamide in rheumatoid arthritis. Arthritis Rheum, 1976, 19, 563-573.
60. Novack, S. N.; Pearson, C. M. Cyclophosphamide therapy in Wegener's granulomatosis. N Engl J Med, 1971, 284, 938-942.
61. Makhani, N.; Gorman, M. P.; Branson, H. M.; Stazzone, L.; Banwell, B. L.; Chitnis, T. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology, 2009, 72, 2076-2082.
62. Slater, L. M.; Stupecky, M.; Sweet, P.; Osann, K. E. Enhancement of leukemia rejection by mice successfully treated for L1210 leukemia due to low dose compared to high dose VP-16. Leuk Res, 2002, 26, 203-206. (Pubitemid 34037857)
63. Schlom, J.; Arlen, P. M.; Gulley, J. L. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res, 2007, 13, 3776-3782. (Pubitemid 47037581)
64. Emens, L. A.; Asquith, J. M.; Leatherman, J. M.; Kobrin, B. J.; Petrik, S.; Laiko, M.; Levi, J.; Daphtary, M. M.; Biedrzycki, B.; Wolff, A. C.; Stearns, V.; Disis, M. L.; Ye, X.; Piantadosi, S.; Fetting, J. H.; Davidson, N. E.; Jaffee, E. M. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol, 2009, 27, 5911-5918.
65. Mattarollo, S. R.; Loi, S.; Duret, H.; Ma, Y.; Zitvogel, L.; Smyth, M. J. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res, 2011, 71, 4809-4820.
66. Tsavaris, N.; Kosmas, C.; Vadiaka, M.; Kanelopoulos, P.; Boulamatsis, D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer, 2002, 87, 21-27.
67. Nowak, A. K.; Lake, R. A.; Robinson, B. W. Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev, 2006, 58, 975-990. (Pubitemid 44780907)
68. Lake, R. A.; Robinson, B. W. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer, 2005, 5, 397-405.
69. Mihich, E.; Ehrke, M. J. Anticancer drugs plus cytokines: immunodulation based therapies of mouse tumors. Int J Immunopharmacol, 2000, 22, 1077-1081. (Pubitemid 32012966)
70. Ewens, A.; Luo, L.; Berleth, E.; Alderfer, J.; Wollman, R.; Hafeez, B. B.; Kanter, P.; Mihich, E.; Ehrke, M. J. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res, 2006, 66, 5419-5426. (Pubitemid 43844969)
71. Stoychkov, J. N.; Schultz, R. M.; Chirigos, M. A.; Pavlidis, N. A.; Goldin, A. Effects of adriamycin and cyclophosphamide treatment on induction of macrophage cytotoxic function in mice. Cancer Res, 1979, 39, 3014-3017. (Pubitemid 9226911)
72. Ujhazy, P.; Zaleskis, G.; Mihich, E.; Ehrke, M. J.; Berleth, E. S. Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunol Immunother, 2003, 52, 463-472. (Pubitemid 36831368)
73. Nowak, A. K.; Robinson, B. W.; Lake, R. A. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res, 2003, 63, 4490-4496. (Pubitemid 36951021)
74. Emens, L. A.; Jaffee, E. M. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res, 2005, 65, 8059-8064. (Pubitemid 41330564)
75. Coleman, S.; Clayton, A.; Mason, M. D.; Jasani, B.; Adams, M.; Tabi, Z. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res, 2005, 65, 7000-7006. (Pubitemid 41060740)
76. Ehrke, M. J.; Verstovsek, S.; Maccubbin, D. L.; Ujhazy, P.; Zaleskis, G.; Berleth, E.; Mihich, E. Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Int J Cancer, 2000, 87, 101-109. (Pubitemid 30368422)
77. Casares, N.; Pequignot, M. O.; Tesniere, A.; Ghiringhelli, F.; Roux, S.; Chaput, N.; Schmitt, E.; Hamai, A.; Hervas-Stubbs, S.; Obeid, M.; Coutant, F.; Metivier, D.; Pichard, E.; Aucouturier, P.; Pierron, G.; Garrido, C.; Zitvogel, L.; Kroemer, G. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med, 2005, 202, 1691-1701. (Pubitemid 41815875)
78. Menard, C.; Martin, F.; Apetoh, L.; Bouyer, F.; Ghiringhelli, F. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother, 2008, 57, 1579-1587.
79. Tanaka, F.; Yamaguchi, H.; Ohta, M.; Mashino, K.; Sonoda, H.; Sadanaga, N.; Inoue, H.; Mori, M. Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. Int J Cancer, 2002, 101, 265-269. (Pubitemid 34970895)
80. Lacour, S.; Hammann, A.; Wotawa, A.; Corcos, L.; Solary, E.; Dimanche-Boitrel, M. T. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res, 2001, 61, 1645-1651. (Pubitemid 34292600)
81. Micheau, O.; Solary, E.; Hammann, A.; Martin, F.; Dimanche-Boitrel, M. T. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst, 1997, 89, 783-789. (Pubitemid 27242279)
82. Gasser, S.; Raulet, D. The DNA damage response, immunity and cancer. Semin Cancer Biol, 2006, 16, 344-347. (Pubitemid 44311502)
83. Gasser, S.; Orsulic, S.; Brown, E. J.; Raulet, D. H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature, 2005, 436, 1186-1190. (Pubitemid 41232299)
84. Obeid, M.; Tesniere, A.; Ghiringhelli, F.; Fimia, G. M.; Apetoh, L.; Perfettini, J. L.; Castedo, M.; Mignot, G.; Panaretakis, T.; Casares, N.; Metivier, D.; Larochette, N.; van Endert, P.; Ciccosanti, F.; Piacentini, M.; Zitvogel, L.; Kroemer, G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med, 2007, 13, 54-61. (Pubitemid 46067386)
85. Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Obeid, M.; Ortiz, C.; Criollo, A.; Mignot, G.; Maiuri, M. C.; Ullrich, E.; Saulnier, P.; Yang, H.; Amigorena, S.; Ryffel, B.; Barrat, F. J.; Saftig, P.; Levi, F.; Lidereau, R.; Nogues, C.; Mira, J. P.; Chompret, A.; Joulin, V.; Clavel-Chapelon, F.; Bourhis, J.; Andre, F.; Delaloge, S.; Tursz, T.; Kroemer, G.; Zitvogel, L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med, 2007, 13, 1050-1059. (Pubitemid 47517504)
86. Melief, C. J. Cancer immunotherapy by dendritic cells. Immunity, 2008, 29, 372-383.
87. Liu, J. Y.; Wu, Y.; Zhang, X. S.; Yang, J. L.; Li, H. L.; Mao, Y. Q.; Wang, Y.; Cheng, X.; Li, Y. Q.; Xia, J. C.; Masucci, M.; Zeng, Y. X. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother, 2007, 56, 1597-1604. (Pubitemid 47094389)
88. Yu, B.; Kusmartsev, S.; Cheng, F.; Paolini, M.; Nefedova, Y.; Sotomayor, E.; Gabrilovich, D. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res, 2003, 9, 285-294. (Pubitemid 36109745)
89. Glynn, J. P.; Halpern, B. L.; Fefer, A. An immunochemotherapeutic system for the treatment of a transplanted Moloney virus-induced lymphoma in mice. Cancer Res, 1969, 29, 515-520.
90. Fefer, A. Immunotherapy and chemotherapy of Moloney sarcoma virusinduced tumors in mice. Cancer Res, 1969, 29, 2177-2183.
91. Mihich, E. Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice. Cancer Res, 1969, 29, 848-854.
92. Vadlamudi, S.; Padarathsingh, M.; Bonmassar, E.; Goldin, A. Effect of combination treatment with cyclophosphamide and isogeneic or allogeneic spleen and bone marrow cells in leukemic (L1210) mice. Int J Cancer, 1971, 7, 160-166.
93. Fass, L.; Fefer, A. Studies of adoptive chemoimmunotherapy of a Friend virus-induced lymphoma. Cancer Res, 1972, 32, 997-1001.
94. Berenson, J. R.; Einstein, A. B., Jr.; Fefer, A. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells. J Immunol, 1975, 115, 234-238.
95. Kedar, E.; Raanan, Z.; Schwartzbach, M. In vitro Induction of Cell-Mediated Immunity to Murine Leukemia Cells. VI. Adoptive Immunotherapy in Combination with Chemotherapy of Leukemia in Mice, Using Lymphoeytes Sensitized in vitro to Leukemia Cells. Cancer Immunol. Immunother., 1978, 4, 161-169. (Pubitemid 9011951)
96. Fujimoto, S.; Greene, M. I.; Sehon, A. H. Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts. J Immunol, 1976, 116, 791-799.
97. Takei, F.; Levy, J. G.; Kilburn, D. G. Characterization of suppressor cells in mice bearing syngeneic mastocytoma. J Immunol, 1977, 118, 412-417. (Pubitemid 8053060)
98. North, R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med, 1982, 155, 1063-1074. (Pubitemid 12142723)
99. Berd, D.; Maguire, H. C., Jr.; Mastrangelo, M. J. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res, 1986, 46, 2572-2577. (Pubitemid 16120733)
100. Berd, D.; Mastrangelo, M. J. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressorinducer T-cells. Cancer Res, 1988, 48, 1671-1675. (Pubitemid 18091225)
101. Mastrangelo, M. J.; Berd, D.; Maguire, H., Jr. The immunoaugmenting effects of cancer chemotherapeutic agents. Semin Oncol, 1986, 13, 186-194. (Pubitemid 16091899)
102. Zhang, T.; Herlyn, D. Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother, 2009, 58, 475-492.
103. Lutsiak, M. E.; Semnani, R. T.; De Pascalis, R.; Kashmiri, S. V.; Schlom, J.; Sabzevari, H. Inhibition of CD4 (+) 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood, 2005, 105, 2862-2868. (Pubitemid 40446280)
104. Ghiringhelli, F.; Larmonier, N.; Schmitt, E.; Parcellier, A.; Cathelin, D.; Garrido, C.; Chauffert, B.; Solary, E.; Bonnotte, B.; Martin, F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol, 2004, 34, 336-344. (Pubitemid 39255944)
105. Sharabi, A.; Laronne-Bar-On, A.; Meshorer, A.; Haran-Ghera, N. Chemoimmunotherapy reduces the progression of multiple myeloma in a mouse model. Cancer Prev Res (Phila), 2010, 3, 1265-1276.
106. Suzuki, E.; Kapoor, V.; Jassar, A. S.; Kaiser, L. R.; Albelda, S. M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res, 2005, 11, 6713-6721. (Pubitemid 41339014)
107. Ko, H. J.; Kim, Y. J.; Kim, Y. S.; Chang, W. S.; Ko, S. Y.; Chang, S. Y.; Sakaguchi, S.; Kang, C. Y. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res, 2007, 67, 7477-7486. (Pubitemid 47206577)
108. Kodumudi, K. N.; Woan, K.; Gilvary, D. L.; Sahakian, E.; Wei, S.; Djeu, J. Y. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res, 2010, 16, 4583-4594.
109. Liao, Y. P.; Schaue, D.; McBride, W. H. Modification of the tumor microenvironment to enhance immunity. Front Biosci, 2007, 12, 3576-3600.
110. Emens, L. A. Cancer vaccines: toward the next revolution in cancer therapy. Int Rev Immunol, 2006, 25, 259-268. (Pubitemid 44972267)
111. Sinkovics, J. G.; Horvath, J. C. Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts. Int J Oncol, 2006, 29, 765-777.
112. Tongu, M.; Harashima, N.; Yamada, T.; Harada, T.; Harada, M. Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma. Cancer Immunol Immunother, 2010, 59, 769-777.
113. Chan, O. T.; Yang, L. X. The immunological effects of taxanes. Cancer Immunol Immunother, 2000, 49, 181-185. (Pubitemid 30484824)
114. Javeed, A.; Ashraf, M.; Riaz, A.; Ghafoor, A.; Afzal, S.; Mukhtar, M. M. Paclitaxel and immune system. Eur J Pharm Sci, 2009, 38, 283-290.
115. Zhong, H.; Han, B.; Tourkova, I. L.; Lokshin, A.; Rosenbloom, A.; Shurin, M. R.; Shurin, G. V. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res, 2007, 13, 5455-5462. (Pubitemid 47510373)
116. Shurin, G. V.; Tourkova, I. L.; Shurin, M. R. Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells. J Immunother, 2008, 31, 491-499.
117. Shurin, G. V.; Tourkova, I. L.; Kaneno, R.; Shurin, M. R. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol, 2009, 183, 137-144.
118. Shurin, G. V.; Tourkova, I. L.; Chatta, G. S.; Schmidt, G.; Wei, S.; Djeu, J. Y.; Shurin, M. R. Small rho GTPases regulate antigen presentation in dendritic cells. J Immunol, 2005, 174, 3394-3400. (Pubitemid 40354044)
119. Whiteside, T. L.; Stanson, J.; Shurin, M. R.; Ferrone, S. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and downregulation by tumor cells. J Immunol, 2004, 173, 1526-1534. (Pubitemid 38971582)
120. Tourkova, I. L.; Shurin, G. V.; Chatta, G. S.; Perez, L.; Finke, J.; Whiteside, T. L.; Ferrone, S.; Shurin, M. R. Restoration by IL-15 of MHC class I antigenprocessing machinery in human dendritic cells inhibited by tumor-derived gangliosides. J Immunol, 2005, 175, 3045-3052. (Pubitemid 41170523)
121. Shurin, G. V.; Amina, N.; Shurin, M. R.: Cancer therapy and dendritic cell immunomodulation. In: Dendritic Cells in Cancer. Edited by R. D. Salter MRS. New York: Springer; 2009:201-216.
122. Kaneno, R.; Shurin, G. V.; Tourkova, I. L.; Shurin, M. R. Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med, 2009, 7, 58.
123. Kaneno, R.; Shurin, G. V.; Kaneno, F. M.; Naiditch, H.; Luo, J.; Shurin, M. R. Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol (Dordr), 2011, 34, 97-106.
124. Shurin, G. V.; Ouellette, C. E.; Shurin, M. R. Regulatory dendritic cells in the tumor immunoenvironment. Cancer Immunol Immunother, 2012, 61, 223-230.
125. Sevko, A.; Kremer, V.; Falk, C.; Umansky, L.; Shurin, M. R.; Shurin, G. V.; Umansky, V. Application of paclitaxel in low noncytotoxic doses supports vaccination with melanoma antigens in mice.. J. Immunotoxicol, 2012, in press.
126. Michels, T.; Shurin, G. V.; Naiditch, H.; Sevko, A.; Umansky, V.; Shurin, M. R. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J. Immunotoxicol, 2012, in press.
127. Orsini, F.; Pavelic, Z.; Mihich, E. Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res, 1977, 37, 1719-1726. (Pubitemid 8098517)
128. Moore, M.; Williams, D. E. Contribution of host immunity to cyclophosphamide therapy of a chemically-induced murine sarcoma. Int J Cancer, 1973, 11, 358-368.
129. Einstein, A. B., Jr.; Cheever, M. A.; Fefer, A. Use of dimethylmyleran in adoptive chemoimmunotherapy of two murine leukemias. J Natl Cancer Inst, 1976, 56, 609-613.
130. Cheever, M. A.; Greenberg, P. D.; Fefer, A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol, 1980, 125, 711-714. (Pubitemid 10005585)
131. Berd, D.; Mastrangelo, M. J.; Engstrom, P. F.; Paul, A.; Maguire, H. Augmentation of the human immune response by cyclophosphamide. Cancer Res, 1982, 42, 4862-4866. (Pubitemid 13206007)
132. Mitsuoka, A.; Baba, M.; Morikawa, S. Enhancement of delayed hypersensitivity by depletion of suppressor T cells with cyclophosphamide in mice. Nature, 1976, 262, 77-78.
133. Glaser, M. Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice. J Exp Med, 1979, 149, 774-779. (Pubitemid 9137688)
134. Haskill, J. S. Adriamycin-activated macrophages as tumor growth inhibitors. Cancer Res, 1981, 41, 3852-3856. (Pubitemid 11011162)